Ultimovacs ASA Company Description

Ultimovacs ASA, a biotech company, develops immunotherapies against cancers in Norway.

Its lead product candidate is UV1, a peptide-based therapeutic cancer vaccine that induces a specific T cell response against the pan-tumor antigen telomerase.

Ultimovacs ASA was incorporated in 2011 and is headquartered in Oslo, Norway.

Ultimovacs ASA

Country	Norway
Founded	2011
Industry	Biological Products, Except Diagnostic Substances
Employees	12
CEO	Hans Eid

Contact Details

Address: Ullernchausséen 64 Oslo, 0379 Norway
Phone	47 41 38 00 80
Website	ultimovacs.com

Stock Details

Ticker Symbol	ZLNA
Exchange	Oslo Børs
Fiscal Year	January - December
Reporting Currency	NOK
SIC Code	2836

Key Executives

Name	Position
Hans Eid	Chief Executive Officer
Hans Eid	Chief Financial Officer